{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040981","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.798238+00:00","generated_at":"2026-06-11T18:01:36.317152+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptevo Q2 net loss $7.9M; APVO436 DOR data positive; $5M raise extends cash into 3Q24","bullets":["Net loss $7.9M ($1.23/share) vs net income $28.0M in Q2 2022 (which included $37.2M gain); cash $21.0M at June 30.","Closed $5M public equity raise on Aug 4, 2023; warrants could add $10M; cash runway now into Q3 2024.","APVO436 + venetoclax + azacitidine in AML: 82% (9/11) response rate for DOR analysis; 3 patients bridged to transplant.","Phase 2 trials for APVO436 planned: relapsed/refractory in 2H23, frontline in 1H24; ALG.APV-527 Phase 1 interim data in 2H23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040981","json":"https://secwatch.observer/filing/0000950170-23-040981.json","markdown":"https://secwatch.observer/filing/0000950170-23-040981.md","text":"https://secwatch.observer/filing/0000950170-23-040981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/0000950170-23-040981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/apvo-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:01:36.317152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80bd7966692cdbc6fdc36313e70395e113278fce","claim":"Aptevo Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/0000950170-23-040981-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}